[Modern treatment of androgenetic alopecia]

Androgenetic alopecia is the most common hair loss, characterized by a chronic and progressive course and a significant psychosocial burden.

The aim of this study was to provide a comparative analysis of current international guidelines and expert consensus statements on the treatment of androgenetic alopecia and to summarize their applicability in clinical practice.

A literature search was performed in the PubMed database to identify English-language guidelines and expert recommendations published between 2015 and 2025. The included documents were analyzed narratively and compared based on therapeutic approaches.

Conventional treatments, including topical minoxidil and 5-alpha-reductase inhibitors, remain the cornerstone of therapy. More recent recommendations increasingly support the use of low-dose oral minoxidil and dutasteride; however, their position varies across guidelines. The role of procedural therapies also differs, mainly due to limited evidence. Differences between recommendations are primarily driven by variability in levels of evidence and the evolving new therapies. In clinical practice, an individualized, multimodal treatment strategy combined with regular follow-up is essential.

The management of androgenetic alopecia is a rapidly evolving field requiring personalized therapeutic decisions. In clinical practice, a personalized combined treatment strategy and regular follow-up are of paramount importance. Orv Hetil. 2026; 167(35): 1385-1393.